Queensland Clinical Guidelines
Translating evidence into best clinical practice

Maternity and Neonatal Clinical Guideline

Term small for gestational age newborn baby
Cultural acknowledgement

The Department of Health acknowledges the Traditional Custodians of the lands, waters and seas across the State of Queensland on which we work and live. We also acknowledge First Nations peoples in Queensland are both Aboriginal Peoples and Torres Strait Islander Peoples and pay respect to the Aboriginal and Torres Strait Islander Elders past, present and emerging.

Disclaimer

This guideline is intended as a guide and provided for information purposes only. The information has been prepared using a multidisciplinary approach with reference to the best information and evidence available at the time of preparation. No assurance is given that the information is entirely complete, current, or accurate in every respect.

The guideline is not a substitute for clinical judgement, knowledge and expertise, or medical advice. Variation from the guideline, taking into account individual circumstances, may be appropriate.

This guideline does not address all elements of standard practice and accepts that individual clinicians are responsible for:

- Providing care within the context of locally available resources, expertise, and scope of practice
- Supporting consumer rights and informed decision making, including the right to decline intervention or ongoing management
- Advising consumers of their choices in an environment that is culturally appropriate and which enables comfortable and confidential discussion. This includes the use of interpreter services where necessary
- Ensuring informed consent is obtained prior to delivering care
- Meeting all legislative requirements and professional standards
- Applying standard precautions, and additional precautions as necessary, when delivering care
- Documenting all care in accordance with mandatory and local requirements

Queensland Health disclaims, to the maximum extent permitted by law, all responsibility and all liability (including without limitation, liability in negligence) for all expenses, losses, damages and costs incurred for any reason associated with the use of this guideline, including the materials within or referred to throughout this document being in any way inaccurate, out of context, incomplete or unavailable.


© State of Queensland (Queensland Health) 2023

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives V4.0 International licence. In essence, you are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute Queensland Clinical Guidelines, Queensland Health and abide by the licence terms. You may not alter or adapt the work in any way. To view a copy of this licence, visit https://creativecommons.org/licenses/by-nc-nd/4.0/deed.en

For further information, contact Queensland Clinical Guidelines, RBWH Post Office, Herston Qld 4029, email Guidelines@health.qld.gov.au. For permissions beyond the scope of this licence, contact: Intellectual Property Officer, Queensland Health, GPO Box 48, Brisbane Qld 4001, email ip_officer@health.qld.gov.au.
Flow Chart: Summary—Term small for gestational age newborn baby

**Growth restriction of the newborn (GRN)**

**Diagnostic criteria**
- BW < 3rd percentile
- OR
- 3 or more of:
  - BW < 10th percentile
  - L < 10th percentile
  - HC < 10th percentile
  - Suspected FGR
  - Current pregnancy risk factor (e.g. congenital infection, hypertension, pre-eclampsia, diabetes)

**Risk factors**
- Primip or grand-multip, short interpregnancy interval
- Ethnicity (e.g. Aboriginal or Torres Strait Islander)
- Low socio-economic status
- Age < 16 or > 35 years
- Suspected FGR
- Previous FGR, SGA, stillbirth
- Co-morbidities (e.g. obesity)
- Substance use (e.g. smoking)
- Mental illness or eating disorder

**Health implications**
- Lower Apgars/acidosis
- Respiratory compromise
- Hypothermia
- Hypoglycaemia
- Hypocalcaemia
- Jaundice
- Feeding intolerance
- Longer term health impacts
  - Neurological delays
  - Obesity
  - Metabolic disorders

**Suspected SGA/GRN**

**Care at birth**
- Anticipate need for resus
- Immediate drying/warmth
- Consider paired BG/lactate
- Support delayed cord clamping (unless required to move for resus)
- Skin to skin
- Recommend placental histopathology
- Feed within 30–60 minutes

**Assessment**
- Review history
- Review EDD
- Plot BW, L, HC on growth charts
- Physical examination
- Assess for features of GRN
- Other assessments as indicated
- Document findings

**Additional care**
- Additional surveillance whilst minimising mother, baby separation
- Low threshold for escalation of care
- Referral as indicated
- Parental information and support

**Care of baby: SGA/GRN**

**Thermoregulation**
- Promote skin to skin
- Check temperature before feeds (at least first 24 hours)
- Delay first bath

**Metabolic**
- Monitor as clinically indicated:
  - Blood glucose
  - Calcium
  - Jaundice

**Feeding**
- Aim is to achieve *gradual* weight gain
- Individualise feeding plan
- Feed at least third hourly
- If PDHM/formula feeding, balance quota with tolerance
- If intolerance seek review
- Consider intravenous therapy or gavage feeds as required

**Discharge considerations**
- Feeding
- Weight
- Maintaining temperature
- Jaundice
- Parental readiness and ability to engage with follow-up

**Follow-up**
- Early post discharge appt
- Assess growth and development up to 2 years

---

**BG** blood gas, **BMI** body mass index, **BW** birth weight, **EDD** estimated due date, **FGR** fetal growth restriction, **GRN** growth restriction in the newborn, **L** length, **HC** head circumference, **PHDM** pasteurised human donor milk, **SGA** small for gestational age, **Resus** resuscitation, < less than, > greater than

Queensland Clinical Guideline: Term small for gestational age newborn baby. Flowchart: F22.16-1-V5-R27
### Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>AC</td>
<td>Abdominal circumference</td>
</tr>
<tr>
<td>EBM</td>
<td>Expressed breastmilk</td>
</tr>
<tr>
<td>EFW</td>
<td>Estimated fetal weight</td>
</tr>
<tr>
<td>FGR</td>
<td>Fetal growth restriction</td>
</tr>
<tr>
<td>GRN</td>
<td>Growth restriction in the newborn/neonate</td>
</tr>
<tr>
<td>SGA</td>
<td>Small for gestational age</td>
</tr>
<tr>
<td>SUPC</td>
<td>Sudden unexpected postnatal collapse</td>
</tr>
</tbody>
</table>

### Definitions

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthropometry</td>
<td>Study of measurements and proportions of the human body.</td>
</tr>
<tr>
<td>Feeding interval</td>
<td>The interval between start of one feed and start of next feed (start to start)</td>
</tr>
<tr>
<td>Growth velocity</td>
<td>The slope of change in fetal biometric percentiles based on gestational age across at least two ultrasounds during pregnancy (e.g. 18 weeks gestation and 32 weeks gestation).</td>
</tr>
<tr>
<td>Neonatal unit</td>
<td>In this guideline, neonatal unit, is used to mean any clinical area where specialised observation, monitoring, and baby care is provided.</td>
</tr>
<tr>
<td>Sudden unexpected postnatal collapse (SUPC)</td>
<td>The sudden cardiorespiratory collapse within the first seven days of life of an apparently healthy newborn born greater than 35 weeks gestation</td>
</tr>
<tr>
<td>Term pregnancy</td>
<td>Gestation greater than or equal to 37 weeks and less than 42 gestational weeks. Further classifications include:</td>
</tr>
<tr>
<td></td>
<td>o Early term (37+0–38+6 weeks)</td>
</tr>
<tr>
<td></td>
<td>o Full term (39+0–40+6 weeks)</td>
</tr>
<tr>
<td></td>
<td>o Late term (41+0–41+6 weeks)</td>
</tr>
<tr>
<td></td>
<td>o Post term (42+0 and beyond).</td>
</tr>
</tbody>
</table>
1 Introduction

Growth is a dynamic process that is assessed over time and is compared to a hypothetical growth potential, represented in growth charts. Human growth is at its greatest during the second half of pregnancy, resulting in a six-fold increase in weight.\(^1\) An interruption in intra-uterine growth places the fetus/baby at increased risk of adverse perinatal mortality and morbidity (e.g. metabolic conditions, neurodevelopmental delay, stillbirth).\(^2,3\)

Obstetric management is focused on identifying the possibility of growth restriction, the underlying causes or contributing factors, monitoring fetal wellbeing during pregnancy and planning birth (timing location, mode of birth) to optimise outcomes.

After birth, individual assessment and risk profiling is essential to identify newborn babies with growth restriction and to balance clinical intervention for improved outcomes.\(^4,5\) This guideline focuses on the term newborn baby (37+0–41+6 weeks gestation) who is small for gestational age (SGA) and/or with growth restriction of the newborn (GRN), and is also applicable to the post-term SGA baby.

1.1 Incidence

In Queensland, approximately 7% of term babies are born less than the 10th percentile.\(^6\) Aboriginal and/or Torres Strait Islander babies are disproportionately represented within the low birth weight population.\(^6\)

Table 1. Queensland birth data

<table>
<thead>
<tr>
<th>Year</th>
<th>Births at term (n)</th>
<th>Indigenous status</th>
<th>Birth weight ≤ 3rd percentile (%)</th>
<th>Birth weight &gt; 3rd and ≤ 10th percentile (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td>56,952</td>
<td>3,662</td>
<td>2.8</td>
<td>1.5</td>
</tr>
<tr>
<td>2017</td>
<td>54,607</td>
<td>3,632</td>
<td>2.9</td>
<td>1.4</td>
</tr>
<tr>
<td>2018</td>
<td>55,023</td>
<td>3,670</td>
<td>3.3</td>
<td>1.4</td>
</tr>
<tr>
<td>2019</td>
<td>54,755</td>
<td>3,920</td>
<td>2.7</td>
<td>1.5</td>
</tr>
<tr>
<td>2020</td>
<td>54,214</td>
<td>3,830</td>
<td>2.9</td>
<td>1.4</td>
</tr>
</tbody>
</table>

Source: Perinatal Data Collection, Department of Health, Department of Health (Queensland)-Statistical Services Branch, 2021.\(^6\)

1.2 Clinical standards

Table 2. Clinical standards

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| Standard care               | • Refer to Queensland Clinical Guideline: Standard care\(^7\) for care considered ‘usual’ or ‘standard’  
                                • Includes for example: privacy, consent, decision making, sensitive communication, medication administration, parental information, staff education and support, culturally appropriate care |
| Model of care               | • Family centred care with developmentally supportive neonatal care\(^8\)                                                                 |
| Clinician education         | • Support learning and education to:  
                                o Promote use of consistent terminology\(^5\)  
                                o Implement supportive care for babies with SGA/GRN\(^8\)  
                                o Improve awareness of common parental experiences and psychological needs (e.g. greater reassurance with feeding)\(^9\)  
                                o Enhance preparation for discharge and improve outcomes relating to maternal readiness\(^10\) |
2 Terminology

During pregnancy, differentiating between SGA and fetal growth restriction (FGR) (also known as intra-uterine growth restriction (IUGR)) remains an obstetric challenge, and terms are often used interchangeably. A more recent term growth restriction of the newborn (GRN) aims to aid the recognition of babies at risk, who might otherwise be missed according to currently accepted definitions and standards.

Table 3 Terminology

<table>
<thead>
<tr>
<th>Small for gestational age (SGA)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Definition</strong></td>
</tr>
<tr>
<td><strong>Categories</strong></td>
</tr>
<tr>
<td>Constitutionally small</td>
</tr>
<tr>
<td>Small due to FGR</td>
</tr>
<tr>
<td><strong>Implications</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Fetal growth restriction (FGR)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Definition</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Categories</strong></td>
</tr>
<tr>
<td>Early onset</td>
</tr>
<tr>
<td>Late onset</td>
</tr>
<tr>
<td>Severe</td>
</tr>
<tr>
<td>Symmetrical</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Asymmetrical</td>
</tr>
<tr>
<td><strong>Implications</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Growth restriction of the newborn (GRN)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Definition</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Implications</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
3 Growth and health

SGA/GRN is an independent risk factor for increased length of hospital stay after birth and readmission during the baby’s first year of life.19

3.1 Short term health risks

Table 4. Short term health implications

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| Resuscitation           | • Babies with birthweight less than the 10th percentile are more likely to experience3:  
  o Neonatal resuscitation (e.g. lower Apgar scores, acidosis, neonatal death)  
  o Respiratory compromise20 (e.g. bronchopulmonary dysplasia, pulmonary hypertension, meconium aspiration syndrome21)  
  • SGA is a recognised risk factor for sudden unexpected postnatal collapse (SUPC)22 |
| Hypothermia             | • Due to20:  
  o Larger surface area to body weight ratio  
  o Higher energy requirements and less glycogen stores  
  o Less body fat and greater proportion of body fluids |
| Nutritional problems    | • Feeding intolerance20  
  • Refer to Section 5.2 Infant feeding |
| Metabolic disturbance   | • Hypoglycaemia (physiological glucose intolerance/insulin resistance)17,23  
  o Refer to Queensland Clinical Guideline: *Hypoglycaemia-newborn*24  
  • Lower rate of fat and protein absorption25  
  • Hypocalcaemia26 |
| Jaundice                | • Greater risk related to polycythaemia25  
  o Refer to Queensland Clinical Guideline: *Neonatal jaundice*27 |

3.2 Longer term health outcomes

Table 5. Longer term health outcomes

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| Expected growth 0–6 months      | • Expected growth from birth to six months25,28  
  o Weight 140–200 grams per week  
  o Head circumference 0.5 cm per week  
  o Length 1.5–2.5 cm per month |
| Catch-up growth                 | • More than 85% of term babies with GRN will achieve catch-up growth in their first 1–2 years of life17,29  
  o The more growth restricted the less the likelihood of attaining a normal height17  
  • Optimal catch-up growth:  
  o Gradually increases over two percentiles during the first several months, (e.g. from less than 10th percentile to between 25th to 50th percentile) then tracks to a median growth by two years30  
  o Minimises long term adverse health outcomes (e.g. rapid growth, overweight/obesity)30  
  • Improved opportunity for optimal catch-up growth occurs when:  
  o Breastmilk is the main source of nutrition31,32  
  o Six hours per day of skin to skin contact (less than two hours per day did not result in significant outcome for weight gain)33 |
| Neurodevelopmental              | • Neurodevelopmental impacts may include delays in cognitive, language and behaviour (e.g. attention, social, emotional) domains34 |
| Endocrine system                | • Increased risk of obesity and metabolic disturbances such as glucose intolerance, insulin resistance, amino acid metabolism17,23,35 |
| Cardiovascular system           | • Increased incidence of hypertension, dyslipidaemia17 and iron deficient anaemia36 |
| Reproductive system             | • Increased incidence of hypospadias, puberty alterations (e.g. earlier age of onset), polycystic ovarian syndrome and subfertility37 |
## Assessment and diagnosis

### 4.1 Risk factors

Table 6. Risk factors

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Demographics</strong></td>
<td>• Ethnicity and maternal place of birth (e.g. Torres Strait Islands, South-East Asia)</td>
</tr>
<tr>
<td></td>
<td>• Age (less than 16 years and greater than 35 years)</td>
</tr>
<tr>
<td></td>
<td>• Lower socioeconomic status</td>
</tr>
<tr>
<td><strong>Obstetric history</strong></td>
<td>• Primiparity or grand multiparity</td>
</tr>
<tr>
<td></td>
<td>• Short interpregnancy interval</td>
</tr>
<tr>
<td></td>
<td>• Multiple pregnancy</td>
</tr>
<tr>
<td></td>
<td>• Inadequate pregnancy weight gain</td>
</tr>
<tr>
<td></td>
<td>• Poor antenatal care</td>
</tr>
<tr>
<td></td>
<td>• Uterine abnormalities</td>
</tr>
<tr>
<td></td>
<td>• Previous baby experiencing:</td>
</tr>
<tr>
<td></td>
<td>• Chromosomal abnormalities</td>
</tr>
<tr>
<td></td>
<td>• Inborn error of metabolism</td>
</tr>
<tr>
<td></td>
<td>• FGR</td>
</tr>
<tr>
<td></td>
<td>• Stillbirth</td>
</tr>
<tr>
<td></td>
<td>• Placental abruption or praevia</td>
</tr>
<tr>
<td></td>
<td>• Pre-eclampsia</td>
</tr>
<tr>
<td><strong>Maternal comorbidities</strong></td>
<td>• Medical conditions (e.g. diabetes, hypertension, thyroid disease, kidney disease)</td>
</tr>
<tr>
<td></td>
<td>• Body mass index (BMI)</td>
</tr>
<tr>
<td></td>
<td>• Less than 18.5 kg/m²</td>
</tr>
<tr>
<td></td>
<td>• 30 kg/m² and above</td>
</tr>
<tr>
<td></td>
<td>• Previous bariatric surgery</td>
</tr>
<tr>
<td></td>
<td>• Micronutrient deficiencies</td>
</tr>
<tr>
<td></td>
<td>• Mental health conditions (e.g. stress)</td>
</tr>
<tr>
<td></td>
<td>• Excessive physical work</td>
</tr>
<tr>
<td><strong>Maternal substance exposure</strong></td>
<td>• Medications (e.g. warfarin, steroids, anticonvulsants, antineoplastics)</td>
</tr>
<tr>
<td></td>
<td>• Substances (e.g. smoking, alcohol)</td>
</tr>
<tr>
<td></td>
<td>• Refer to Queensland Clinical Guideline: Perinatal substance use: maternal</td>
</tr>
<tr>
<td></td>
<td>• Environmental exposures (e.g. disinfectants)</td>
</tr>
<tr>
<td><strong>Placental</strong></td>
<td>• Abnormalities (e.g. velamentous cord insertion)</td>
</tr>
<tr>
<td></td>
<td>• Single umbilical artery</td>
</tr>
<tr>
<td></td>
<td>• Placental infarctions</td>
</tr>
<tr>
<td></td>
<td>• Infection</td>
</tr>
<tr>
<td><strong>Baby</strong></td>
<td>• Congenital infections (e.g. syphilis, toxoplasmosis, rubella, cytomegalovirus (CMV), herpes)</td>
</tr>
<tr>
<td></td>
<td>• Genetic factors involved in approximately half of FGR</td>
</tr>
<tr>
<td></td>
<td>• Anomalies:</td>
</tr>
<tr>
<td></td>
<td>• Chromosomal abnormality (e.g. trisomy 13, 18, 21)</td>
</tr>
<tr>
<td></td>
<td>• Major anomalies (e.g. omphalocele, neural tube defect)</td>
</tr>
<tr>
<td></td>
<td>• Congenital heart defects (e.g. Tetralogy of Fallot, ventricular septal defect requiring surgery)</td>
</tr>
</tbody>
</table>
4.2 Assessment
Identifying and differentiating between a normal growth baby and one who is growth restricted, is based on a combination of assessment, risk factors, overall size and the clinical picture.\(^48\)

Table 7. Assessment

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| **History**     | • Review maternal and birth history to identify associated factors\(^41\)  
|                 |   o Consider size of parents and familial growth patterns that may support baby being constitutionally small  
|                 |   o Consider the accuracy of the estimated prenatal gestational age\(^49\)  
|                 | • Refer to 4.1 Risk factors                                                                                                                                 |
| **Anthropometry**| • Measure and plot birth weight, length and head circumference according to gestational age and sex  
|                 | • Compare head circumference to weight and length, to support clinical interpretation\(^25\)                                                                                                                                 |
| **Physical features**| • Perform a clinical examination of the newborn  
|                 |   o Refer to Queensland Clinical Guideline: Newborn baby assessment (routine)\(^30\)  
|                 |   • Assess for features of GRN including\(^17\):  
|                 |     o Wizened appearance, general lack of subcutaneous fat, decreased skeletal mass, hyper alert  
|                 |     o Dysmorphic features (e.g. babies with genetic disorders, congenital infections)  
|                 |     o Skin cracked, peeling and loose skin folds  
|                 |     o Larger head-to-body ratio  
|                 |     o Large anterior fontanelle  
|                 |     o Thin, smooth, straight hair  
|                 |     o Immature ear cartilage  
|                 |     o Absent buccal fat  
|                 |     o Meconium stained umbilical cord  
|                 |     o Diminished breast buds  
|                 |     o Small, scaphoid shaped abdomen  
|                 |     o Immature labia majora in females  
|                 |     o Hands and feet appear large  
|                 |     o Long fingernails  
| **Other tools** | • If gestational age is uncertain, (e.g. no early ultrasound) a physical assessment may assist estimation:  
|                 |   o New Ballard method: FGR may increase inaccuracy of score (e.g. diminished vernix, reduced amniotic fluid, dry skin)\(^17\)  
|                 |   o Dubowitz method: more comprehensive tool\(^51\)  
|                 | • Clinical assessment of nutrition (CAN) score  
|                 |   o Scores subcutaneous and muscle mass to determine nutritional status\(^17\)  
|                 | • Ponderal index  
|                 |   o Determines level of malnourishment\(^17\)  
|                 | • Ratio of newborn mid-arm circumference to head circumference to identify insufficient birth weight\(^17\)  

4.2.1 Growth charts

Table 8. Growth charts

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Context</td>
<td>• Represent expected growth potential</td>
</tr>
<tr>
<td></td>
<td>• Population and customised charts can both aid identification of SGA/GRN⁶</td>
</tr>
<tr>
<td></td>
<td>• Lack of high level evidence to support use of one growth chart over another¹²,⁵²</td>
</tr>
<tr>
<td></td>
<td>• Variations in metrics may result in different cut off points for FGR/SGA/GRN⁵³</td>
</tr>
<tr>
<td></td>
<td>• Controversy exists regarding concepts and modelling, such as⁵⁴:</td>
</tr>
<tr>
<td></td>
<td>o Growth charts assume constant growth</td>
</tr>
<tr>
<td></td>
<td>o Increasing rates of intervention (e.g. induction of labour, elective caesarean) have altered term gestation percentiles⁵⁵</td>
</tr>
<tr>
<td>Commonly used growth charts</td>
<td>• World Health Organization (WHO) growth charts are used in the baby’s personal health record (Red Book (or Blue Book for NSW babies)⁵⁶</td>
</tr>
<tr>
<td></td>
<td>• Fenton growth charts are widely used in Australia⁵⁷</td>
</tr>
<tr>
<td></td>
<td>o Data compiled from developed countries, including Australia¹</td>
</tr>
<tr>
<td></td>
<td>o Blend into the WHO growth charts</td>
</tr>
<tr>
<td></td>
<td>• Customised Australian birth weight percentiles have been developed but lack validation⁵⁷</td>
</tr>
<tr>
<td>Recommendation</td>
<td>• Use either the Fenton growth charts or the WHO growth charts to plot weight</td>
</tr>
<tr>
<td></td>
<td>• Determine choice of growth chart at the facility level and use across the service to promote consistent clinical interpretation</td>
</tr>
<tr>
<td></td>
<td>• At discharge, transfer the measurements into the baby’s personal health record⁵ (WHO growth chart)</td>
</tr>
</tbody>
</table>

4.2.2 Quick guide estimates to growth restriction

Table 9. Estimates of growth restriction using Fenton growth charts

<table>
<thead>
<tr>
<th>Gestation</th>
<th>Percentile</th>
<th>Boy</th>
<th>Girl</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>BW (g)</td>
<td>L (cm)</td>
</tr>
<tr>
<td>37+0 weeks</td>
<td>3rd</td>
<td>2150</td>
<td>43.8</td>
</tr>
<tr>
<td></td>
<td>10th</td>
<td>2400</td>
<td>45.2</td>
</tr>
<tr>
<td>38+0 weeks</td>
<td>3rd</td>
<td>2350</td>
<td>45.0</td>
</tr>
<tr>
<td></td>
<td>10th</td>
<td>2600</td>
<td>46.2</td>
</tr>
<tr>
<td>39+0 weeks</td>
<td>3rd</td>
<td>2550</td>
<td>46.0</td>
</tr>
<tr>
<td></td>
<td>10th</td>
<td>2800</td>
<td>47.3</td>
</tr>
<tr>
<td>40+0 weeks</td>
<td>3rd</td>
<td>2750</td>
<td>47.0</td>
</tr>
<tr>
<td></td>
<td>10th</td>
<td>3000</td>
<td>48.3</td>
</tr>
<tr>
<td>41+0 weeks</td>
<td>3rd</td>
<td>2910</td>
<td>48.0</td>
</tr>
<tr>
<td></td>
<td>10th</td>
<td>3200</td>
<td>49.2</td>
</tr>
</tbody>
</table>

Measurements approximated using the Fenton 2013 growth calculator⁵⁸
## 4.3 Diagnosis and investigations

Accurate diagnosis is key to implementing early intervention, follow-up monitoring and improved health outcomes.\(^{11}\)

### Table 10. Diagnostic and investigations

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| Diagnostic criteria  | • Use GRN diagnostic criteria to improve detection rates  
|                      |   o Refer to Section 2 Terminology  
|                      |   • Document clinical decision making process and criteria used to differentiate between normal growth and SGA/GRN (e.g. presence and absence of physical features, additional tools used for assessment)  |
| Investigations       | • Individualise according to clinical circumstances, consider (particularly if antenatal care limited or absent):  
|                      |   o Maternal toxoplasmosis, rubella, herpes screen, syphilis  
|                      |   o Urine CMV polymerase chain reaction (PCR)\(^ {59}\)  
|                      |   o Karyotype\(^ {58}\)  
|                      |   o Cranial ultrasound\(^ {59}\)  
|                      | • Placental histopathology recommended if\(^ {12,46}\):  
|                      |   o Placental vascular malperfusion lesions  
|                      |   o Increased neonate-to-placenta weight ratio (associated with recurrent SGA/GRN)  
|                      |   o Placental weight less than 350 grams\(^ {39}\)  
|                      | • If suspicion of abnormalities, (e.g. dysmorphic features), consider\(^ {60}\):  
|                      |   o Dysmorphology assessment and molecular genetic testing\(^ {60}\)  
|                      |   o Ophthalmology assessment  |
| Communication and referral | • Discuss findings with family\(^ {17}\)  
|                      | • Refer to specialists as required (e.g. geneticist)  |
5 Supportive care
A focus on keeping baby “warm, pink and sweet”, whilst monitoring for any clinical compromise, is the mainstay of care for most well babies who are SGA or have GRN.25

5.1 Newborn care

Table 11. Newborn care

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| **At birth**                  | • Anticipate need for resuscitation\(^3\)  
  o Refer to Queensland Clinical Guideline: *Neonatal resuscitation*\(^61\)  
  • Immediate drying or occlusive wraps (high risk of hypothermia)\(^25\)  
  • Promote skin to skin contact\(^53\) and support with warm wraps/blankets (with safe positioning of upper airway)  
  • Delay cord clamping to increase iron stores (no increased morbidities associated with SGA/GRN and polycythaemia)\(^36\)  
  • Consider paired cord blood gases\(^12\)  
  • Record first temperature  
  • Commence feeding within 30–60 minutes\(^20,25\)  
  • Examine placenta and consider histopathology\(^12,46\)  |
| **Clinical surveillance**     | • Support mother and baby togetherness, minimise separation\(^8\)  
  o SGA/GRN alone is not an indication for admission to a neonatal unit  
  o Follow local protocols for criteria for admission to a neonatal unit  
  • SGA baby requires close surveillance in the postnatal area\(^17,22\)  
  • Support care provision to minimise/prevent\(^25\):  
  o Hypothermia  
  o Respiratory compromise  
  o Hypoglycaemia  
  • Blood glucose monitoring  
  o Refer to Queensland Clinical Guideline: *Hypoglycaemia-newborn*\(^24\)  
  • Clinical observations as per neonatal early warning tool (NEWT)\(^62\)  
  o Take temperature prior to feeds for first 24 hours  
  o Maintain low threshold for escalation of care  
  • Monitor input and output  
  • If clinical deterioration, transfer care as per local protocols  
  o Refer to Queensland Clinical Guidelines: *Neonatal stabilisation for retrieval*\(^63\)  |
| **Thermoregulation**          | • Limit exposure to environmental temperature variations to conserve energy resources\(^25,64\)  
  o Maintain thermoneutral environment (draft free environment, room temperature at least 25 °C)  
  o Skin to skin contact supports neonatal thermoregulation  
  o Use warm wraps/blankets to support skin to skin contact  
  o If required, use external heat sources (e.g. radiant warmer)  
  o Delay first bath at least until after the first 24 hours\(^65\)  |
| **Jaundice**                  | • Monitor for jaundice due to associated polycythaemia\(^25,66\)  
  o Refer to Queensland Clinical Guideline: *Neonatal jaundice*\(^24\)  |
| **Metabolic disturbances**    | • Maintain awareness of increased risk of hypo/hyperglycaemia within the first 48 hours of life\(^25\)  
  o Refer to Queensland Clinical Guideline: *Hypoglycaemia-newborn*\(^24\)  
  • If baby unwell, consider screening for hypocalcaemia\(^66\)  |
5.2 Infant feeding

Babies with limited reserves (e.g. early term) are more likely to tire easily, have inefficient suck and swallow, and less milk transfer.28

Table 12. Infant feeding

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| Breastfeeding    | • Breastfeeding improves health outcomes for SGA/GRN babies31,32  
|                  |   o Healthier catch-up growth and less adiposity and insulin resistance  
|                  |   o If preferred feeding method, recommend early lactation support (e.g. lactation consultation, assistance with expressing/storing expressed  
|                  |     breastmilk (EBM) after feeds, support for supply concerns)  
|                  |   o Refer to Queensland Clinical Guideline: Establishing breastfeeding67                                                                   |
| Feeding support  | • Develop an individualised feeding plan with parents28  
|                  |   o Feed at least every three hours and monitor frequency  
|                  |   o Calculate feeding interval from start of one feed to start of next feed  
|                  |   o Observe and assess an entire feed at regular intervals (e.g. each shift) (e.g. nutritive versus non-nutritive sucking, if baby tiring)  
|                  |   o Consider pasteurised donor human milk (PDHM) if available25  
|                  |   o If PDHM/formula feeding, balance quota with tolerance of feeds  
|                  |   o Monitor for vomiting, signs of feed intolerance20                                                                                     |
| Feeding concerns | • If after the first feed, baby has not fed in a three-hour interval (calculate interval from start of one feed to start of next feed)  
|                  |   o Review previous feeding history, urinary output, bowel motions (type, colour, and frequency)  
|                  |   o Assess baby (e.g. temperature, heart rate, respirations, colour)  
|                  |   o Review lactation support and feeding plan  
|                  |   o Consider early paediatric/neonatal team notification and review  
|                  | • If feeding concerns, consider as indicated:  
|                  |   o Limiting length of feed (e.g. 20–30 minutes)28  
|                  |   o Gavage, supplementation (EBM, PDHM or formula) or IV fluids20  
|                  |   o Gradual increase of enteral feeds accompanied by IV fluids20  
|                  |   o Speech pathologist assessment for feeding safety                                                                                     |

5.3 Parental support

Table 13. Parental support

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| Parental support | • Advise parents about9:  
|                  |   o Essential elements of care (e.g. thermoregulation, feeding frequency)  
|                  |   o Additional benefits of breastfeeding/breastmilk for SGA/FGR baby31,32  
|                  |   o Benefits of skin to skin—positioned to support adequate airway22,68  
|                  |   o When to seek urgent assistance (e.g. baby’s colour changes, breathing concerns, floppy tone)22,68  
|                  | • Offer additional information about:  
|                  |   o Recognising feeding cues, suck types (e.g. nutritive), feeding behaviours (e.g. tiring during feeds)9  
|                  |   o Common feelings experienced (e.g. unpreparedness, guilt, focus and concern about feeding, fatigue)9  
|                  |   o Bonding and attachment through positive parent-infant strategies8,69  
|                  |   o Community resources (e.g. web based, support services/groups)  
|                  |   o Refer to multidisciplinary team for additional support as indicated (e.g. social work, perinatal mental health)                      |
| Impact on future | • Discuss impact on future pregnancies  
| pregnancy        |   o Increased risk of future babies with SGA/GRN46  
|                  |   o Cumulative risk if other pregnancy risk factors exist (e.g. previous preterm birth or stillbirth)70  
|                  |   o Benefits of early engagement in pregnancy care and additional interventions according to risks (e.g. low dose aspirin)12  
|                  | • Offer support to reduce modifiable risk factors (e.g. smoking cessation,  
|                  |   o Refer for specialist support (e.g. Alcohol and Drug Service)12  

Refer to online version, destroy printed copies after use
6 Discharge planning and follow-up

Table 14. Discharge and follow-up

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Consideration</th>
</tr>
</thead>
</table>
| Context                        | • SGA/GRN have higher rates of hospital readmission due to health concerns, increased risk of jaundice and subsequent feeding challenges  
• Initial baby follow-up appointments within 72 hours of discharge have led to a 15% reduction in readmission rates71 |
| Readiness for discharge        | • Involve parents early, discuss timing and make a plan for discharge20  
• Consider delaying discharge (or advising against early discharge) as may:  
o Increase opportunity to establish maternal and newborn readiness  
o Mitigate increased risk of readmission  
• If baby has been cared for in a neonatal unit, consider additional time for rooming-in20  
• In addition to usual discharge criteria25:  
o Baby is clinically stable (all vital signs within normal limits, maintains own temperature)  
o Baby is feeding adequately  
o Weight gain or loss is appropriate within the context of individualised clinical assessment  
o Review for jaundice (common reason for readmission72,73,74)  
o Parent(s) able/willing to engage with follow-up services |
| Additional information for parent/s | • Discuss importance of follow-up  
o Often growth monitoring occurs only after developmental concerns are identified30  
• Document referral plan in the baby’s personal health record (e.g. Red Book (or Blue Book for NSW babies))  
• Offer information about:  
o Nutritional/feeding requirements  
o Gradual nature of catch up growth [refer to Table 5. Longer term health outcomes]  
• Provide parent information sheet (e.g. Queensland Clinical Guidelines: Small baby born at term) |
| Initial follow-up              | • Recommend early follow-up  
o If baby born early term, contact within 48 hours28  
o If discharge is within 48 hours of birth, contact within 2–3 days  
• Following initial review (e.g. by home visiting maternity service), refer for ongoing follow up (e.g. child health services or general practitioner (GP)) |
| Ongoing follow-up              | • Recommend follow-up assessment and growth monitoring up to at least two years of age, by a paediatric care provider17,34,75 (e.g. child health services, GP, paediatrician, allied heath)  
• Consider as indicated:  
o Cardiovascular health  
o Metabolic parameters  
o Neurodevelopmental assessment and early intervention34  
• Referral to specialist staff |
Queensland Clinical Guideline: Term small for gestational age newborn baby


Appendix A: Fenton Growth Charts (boys and girls)
Acknowledgements
Queensland Clinical Guidelines gratefully acknowledge the contribution of Queensland clinicians and other stakeholders who participated throughout the guideline development process particularly:

Working Party Clinical Leads
Dr Kirsty Devine, Neonatologist, Townsville University Hospital
Ms Annandrea Flint, Neonatal Nurse Practitioner, Redcliffe Hospital

QCG Program Officer
Ms Janene Rattray, Clinical Midwife/Nurse Consultant, Queensland Clinical Guidelines

Working Party Members
Dr Rebekah Adams, GP Obstetrician, Kingaroy Hospital
Mrs Carole Allington, Registered Midwife/Clinical Nurse, Logan Hospital
Mrs Seija Argyros, Neonatal Nurse Practitioner, Royal Brisbane and Women's Hospital
Dr Simon Arnold, Rural Obstetrics and Gynaecology Clinical Lead, Darling Downs Hospital and Health Service
Dr Elize Bolton, Clinical Director, Bundaberg Hospital
Professor Leonie Callaway, Obstetric Physician, Royal Brisbane and Women's Hospital
Ms Nicole Chappell, Registered Midwife/Nurse, Child Protection Liaison Officer, Townsville University Hospital
Ms Rachelle Chee, Associate Lecturer, Central Queensland University
Dr Lindsay Cochrane, Obstetrician, Caboolture Hospital
Ms Li-an Collie, Nurse Educator, Royal Brisbane and Women's Hospital
Ms Eileen Cooke, Consumer Representative, Preterm Infants Parents' Association
Miss Jeanie Cooper, Clinical Midwife, Redcliffe Hospital
Dr Mark Davies, Neonatologist, Royal Brisbane and Women's Hospital
Dr Daniel Dorevitch, Neonatal/Paediatrics Advanced Trainee, Cairns Hospital
A/Professor Greg Duncombe, Pre-eminent Senior Staff Specialist, Royal Brisbane and Women's Hospital
Ms Judy Foote, Registered Midwife/Nurse, Townsville University Hospital
Ms Jennifer Fry, Registered Midwife, Beaudesert Hospital
Dr Sabaratnam Ganeshanathan, Clinical Director, Hervey Bay and Maryborough Hospitals
Mrs Michelle Gavin, Clinical Nurse, Royal Brisbane and Women's Hospital
Ms Tonya Gibbs, Nurse Educator, Sunshine Coast University Hospital
Dr Leigh Grant, Senior Medical Officer, Rockhampton Hospital
Mrs Marie Hall, Clinical Nurse Consultant, Central Queensland Hospital and Health Service
Dr Shivanand Hebbandi, Paediatrician, Redland Hospital
Miss Jane Hitchcock, Registered Midwife, Redland Hospital
Mrs Julianne Hite, Clinical Nurse/Neonatal Nurse Educator, Rockhampton Hospital
Ms Karen Hose, Neonatal Nurse Practitioner, Royal Brisbane and Women's Hospital
Mrs Kristin Hughes, Clinical Nurse, Sunshine Coast University Hospital
Ms Frances Keemer, Registered Midwife/Lactation Consultant, Kingaroy Hospital
Ms Janelle Laws, Registered Nurse/Midwifery Educator, Metro North Hospital and Health Service
Mrs Nicole Lindenberg, Registered Midwife/Nurse, Mater Misericordiae Hospital
Dr Jane Maher, Obstetrician, Sunshine Coast University Hospital
Dr Poliana de Barros Meireiros, Neonatal Senior Medical Officer, Sunshine Coast University Hospital
A/Professor Kassam Mahomed, Senior Medical Officer, Ipswich Hospital
Mrs Catherine Martin, Clinical Midwife Consultant, Rockhampton Hospital
Ms Melanie McKenzie, Consumer Representative, Harrison's Little Wings Inc
Ms Remai Mitchell, Registered Midwife, Centre for Child Health Research
Mrs Sarah Moulton, Clinical Nurse/Lactation Consultant, Wesley Hospital and Mater Mothers' Hospital
Dr Scott Petersen, Maternal-Fetal Medicine Specialist, Mater Mothers' Hospital
Dr Amita Roy, Obstetrician, Gladstone Hospital
Dr Peter Schmidt, Director of Neonatology, Gold Coast University Hospital
Dr Prasanna Shirkhedkar, Senior Staff Specialist, Caboolture Hospital
Ms Aecia Staines, Consumer Representative, Maternity Consumer Network
Ms Kelly Stegmann, Registered Midwife, Ipswich Hospital
Dr Christina White, Paediatrician, Bundaberg Hospital
Mrs Deborah Wright, Clinical Nurse, Sunshine Coast University Hospital

Queensland Clinical Guidelines Team
Professor Rebecca Kimble, Director
Ms Jacinta Lee, Manager
Ms Stephanie Suthers, Clinical Nurse Consultant
Ms Cara Cox, Clinical Nurse Consultant
Ms Emily Holmes, Clinical Nurse Consultant
Ms Janene Rattray, Clinical Nurse Consultant
Steering Committee

Funding
This clinical guideline was funded by Healthcare Improvement Unit, Queensland Health